Authors
Huiwen Yang, Shuqiao Zheng, Jiaohui Pang, Jinming Yu, Linlin Wang
Published in
Thoracic cancer. Volume 17. Issue 14. Pages e70348.
Abstract
Anaplastic lymphoma kinase (ALK) rearrangements are rare in lung squamous cell carcinoma (LSCC), with the clinical efficacy of ALK tyrosine kinase inhibitors (TKIs) in patients harboring uncommon ALK fusions remaining poorly characterized. We report here the first identification of a novel MTHFD1L-ALK fusion in a 63-year-old male with a heavy smoking history diagnosed with stage IIIC LSCC. The patient initially received induction therapy with the ALK TKI iruplinalkib, achieving a best response of stable disease (SD). Although subsequent chemoradiotherapy yielded a partial response (PR), disease progression occurred after four cycles of maintenance iruplinalkib, with a progression-free survival (PFS) of 8.28 months. Subsequent lorlatinib provided limited benefit, with disease progression at 5.3 months following treatment self-discontinuation. Retrospective immunohistochemical staining of ALK (D5F3) was negative despite the positive genomic finding. This case demonstrates limited clinical benefit from ALK inhibitors in LSCC with this novel fusion, expands the known mutational spectrum in non-small cell lung cancer (NSCLC), and underscores the critical importance of confirming novel fusions at the protein expression level through multimodal testing.
PMID:
42473299
Bibliographic data and abstract were imported from PubMed on 20 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0